News

Mark D. Tyson, II, MD, MPH, concludes his conversation on the BOND-003 trial by discussing the next steps for research on cretostimogene grenadenorepvec.

The combination of pembrolizumab, trastuzumab, and chemotherapy showed significant improvement in overall survival vs placebo in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

Here are the latest FDA approvals, designations, and decisions from April 2024.

A pivotal phase 2 study evaluating glecirasib for the treatment of KRAS G12C-mutated advanced non-small cell lung cancer met its primary end point with an encouraging overall response rate.

Regina Barragan-Carrillo, MD, discusses results of a study which sought to assess the association between thymectomy and incidence of renal cell carcinoma.

A recent article pointed out that efforts to decrease low-value care often fall short. It asserted that a primary cause is physicians being financially motivated.

The FDA issued a ‘safe to proceed’ for the investigational new drug application for PRAME TCR/IL-15 NK for relapsed or refractory myeloid malignancies.

Nivolumab monotherapy plus salvage nivolumab/ipilimumab demonstrated superior treatment-free survival rates among patients with advanced renal cell carcinoma, especially in patients with favorable risk profiles.

Although immune checkpoint inhibitors have become a cornerstone of therapy across cancer settings, their use in most breast cancer settings has fallen short.

Tisotumab vedotin is now an FDA-approved treatment for patients with recurrent or metastatic cervical cancer.

Lori J. Wirth, MD, discusses some of the ongoing clinical trials investigating innovative therapies or combinations for the treatment of patients with thyroid cancer.

Clinical trials play a pivotal role in developing effective therapies, yet their integration is challenged by issues such as insufficient reimbursement structures, misaligned incentives, physician burnout, and a complex regulatory environment.

Lucia Masarova, MD, PhD, elaborated on the latest updates across myeloproliferative neoplasms, focusing on significant studies and emerging therapeutic approaches.

Trastuzumab-strf, a biosimilar of trastuzumab, has received FDA approval for treating HER2-overexpressing breast cancer and metastatic gastric cancer.

New data from the DESTINY-Breast06 trial indicate that trastuzumab deruxtecan could become a new standard of care for patients with HER2-low and HER2-ultralow metastatic breast cancer.

Updated guidelines for small cell lung cancer were developed with an expert panel assembled by the American Society of Clinical Oncology and Ontario Health.

Recent FDA approvals such as tovorafenib, nogapendekin, and alectinib, are included in this recap. We also cover boxed warnings for CAR T-cell therapies and analysis advancements for papillary thyroid microcarcinoma.

Targeted therapies and immunotherapies across the ovarian, endometrial, and cervical cancers landscape play expanded roles, according to Ritu Salani, MD, MBA.

Ariel Lopez-Chavez, MD, discusses the potential of tarlatamab and its use in the frontline setting for the treatment of patients with small cell lung cancer.

In a retrospective study in patients with hepatocellular carcinoma, 40% of patients developed irAEs after receiving the first and second doses of immunotherapy.

Binod Dhakal, MD, MS, discusses the potential risk of secondary cancers like lymphoma and leukemia sometimes seen with chimeric antigen receptor T-cell therapies.

In an interview with Targeted Oncology for Head and Neck Cancer Awareness Month, Noel Laudi, MD, MRCP, discussed the link between human papillomavirus infection and head and neck cancers.

In the frontline, patient body mass index plays a prognostic role when using atezolizumab plus bevacizumab vs lenvatinib for patients with advanced hepatocellular carcinoma.

Sanjay K. Juneja, MD, Targeted Oncology’s first 2024 Oncology Icon, delves into his background and what drove him to pursue a career in oncology.

Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.

John M. Burke, MD, discusses results from a phase 2 study which evaluated brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for the treatment of early-stage and advanced classical Hodgkin lymphoma.

In an interview with Targeted Oncology, Ben Jones identified the key challenges community oncologists are facing due to legislative changes in cancer care policy.